Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modelingopen access
- Authors
- Kang, Soyoung; Yang, Seungwon; Hahn, Jongsung; Jang, June Young; Min, Kyoung Lok; Wi, Jin; Chang, Min Jung
- Issue Date
- Nov-2022
- Publisher
- MDPI
- Keywords
- meropenem; extracorporeal membrane oxygenation; ECMO; dosage optimization; population pharmacokinetics
- Citation
- JOURNAL OF CLINICAL MEDICINE, v.11, no.22
- Journal Title
- JOURNAL OF CLINICAL MEDICINE
- Volume
- 11
- Number
- 22
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86431
- DOI
- 10.3390/jcm11226621
- ISSN
- 2077-0383
- Abstract
- Background: Our objective was to determine an optimal dosage regimen of meropenem in patients receiving veno-arterial extracorporeal membrane oxygenation (V-A ECMO) by developing a pharmacokinetic/pharmacodynamic (PK/PD) model. Methods: This was a prospective cohort study. Blood samples were collected during ECMO (ECMO-ON) and after ECMO (ECMO-OFF). The population pharmacokinetic model was developed using nonlinear mixed-effects modeling. A Monte Carlo simulation was used (n = 10,000) to assess the probability of target attainment. Results: Thirteen adult patients on ECMO receiving meropenem were included. Meropenem pharmacokinetics was best fitted by a two-compartment model. The final pharmacokinetic model was: CL (L/h) = 3.79 x 0.44(CRRT), central volume of distribution (L) = 2.4, peripheral volume of distribution (L) = 8.56, and intercompartmental clearance (L/h) = 21.3. According to the simulation results, if more aggressive treatment is needed (100% fT > MIC target), dose increment or extended infusion is recommended. Conclusions: We established a population pharmacokinetic model for meropenem in patients receiving V-A ECMO and revealed that it is not necessary to adjust the dosage depending on V-A ECMO. Instead, more aggressive treatment is needed than that of standard treatment, and higher dosage is required without continuous renal replacement therapy (CRRT). Also, extended infusion could lead to better target attainment, and we could provide updated nomograms of the meropenem dosage regimen.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/86431)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.